How to cite item

Plasma miR-142 predicts major adverse cardiovascular events as an intermediate biomarker of dual antiplatelet therapy

   
@article{APS9916,
	author = {Qian-jie Tang and He-ping Lei and Hong Wu and Ji-yan Chen and Chun-yu Deng and Wang-sheng Sheng and Yong-heng Fu and Xiao-hong Li and Yu-bi Lin and Ya-ling Han and Shi-long Zhong},
	title = {Plasma miR-142 predicts major adverse cardiovascular events as an intermediate biomarker of dual antiplatelet therapy},
	journal = {Acta Pharmacologica Sinica},
	volume = {40},
	number = {2},
	year = {2019},
	keywords = {},
	abstract = {MicroRNAs (miRNAs) are widely expressed in organisms and are implicated in the regulation of most biological functions. The present study investigated the association of plasma miRNAs with the clinical outcomes of dual antiplatelet therapy in coronary artery disease (CAD) patients who underwent percutaneous coronary intervention (PCI). Plasma miRNA levels were screened using high-throughput Illumina sequencing to evaluate the antiplatelet efficacy of clopidogrel and aspirin. Six plasma miRNAs (miR-126, miR-130a, miR-27a, miR-106a, miR-21, and miR-142) were associated with clopidogrel-treated platelet aggregation. These miRNAs were validated in a prospective cohort of 1230 CAD patients using quantitative reverse transcription-polymerase chain reaction (qRT-PCR). High plasma miR-142 levels were associated with a high risk of major adverse cardiovascular events (MACE), with a hazard ratio (95% confidence interval) of 1.83 (1.30–2.59) at a false discovery rate of },
	issn = {1745-7254},	url = {http://www.chinaphar.com/article/view/9916}
}